AJP - Endo AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (October 27, 2009). doi:10.1152/ajpendo.00234.2009
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Westwood, M.
Right arrow Articles by Clayton, P. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westwood, M.
Right arrow Articles by Clayton, P. E.

RESEARCH ARTICLE

The effect of different patterns of growth hormone administration on the IGF axis, somatic and skeletal growth of the dwarf rat

Melissa Westwood,1,* Arfa R Maqsood,1 Mattea Solomon,1 Andrew J Whatmore,1 Julian RE Davis,2 Robert C. Baxter,3 Evelien F Gevers,4 Iain CAF Robinson,4 and Peter E. Clayton1

1University of Manchester 2Endocrine Sciences Research Group 3University of Sydney 4National Institute for Medical Research, UK

Submitted 7 April 2009 ; revised 21 October 2009 ; accepted in final form 22 October 2009

Normal childhood growth is determined by ultradian and infradian variations in GH secretion, yet GH treatment of children with short stature is restricted to daily fixed doses. We have used GH-deficient dwarf rats to determine if variable GH dose regimens promote growth more effectively than fixed doses. Animals were treated with saline or 4.2mg recombinant bovine GH given as 1) 700µg/week in 100µg/day doses, 2) alternating weekly doses of 966µg (138µg/day) or 434µg (62µg/day) or 3) 700µg/week in randomised daily doses (5-250µg/day). Body weight and length were measured weekly. Femur and tibia lengths and internal organ, fat pad and muscle weights were recorded at the end of the study (6 weeks); blood was collected for IGF axis measurements. GH promoted femur (F(3,60)=14.67, p<0.05), tibia (F(3,60)=14.90, p<0.05), muscle (F(3,60)=10.37, p<0.05) and organ growth (liver: F(3,60)=9.30, p<0.05; kidney: F(3,60)=2.82, p<0.05) and an increase in serum IGF-I (F(3,60)=9.18, p<0.05) and IGFBP-3 (F(3,60)=6.70; p<0.05) levels. IGF-I levels correlated with final weight (r=0.45, p<0.05) and length (r=0.284, p<0.05) in the whole cohort but within each group, growth parameters correlated with serum IGF-I only in animals treated with random GH doses. The variable regimens promoted femur length (p<0.05), muscle (p<0.05) and kidney (p<0.05) weight more effectively than treatment with the fixed regimen. This study demonstrates that aspects of growth are improved following introduction of infradian variation to GH treatment in a GH-deficient model. The data suggest that varying the pattern of GH doses administered to children may enhance growth performance without increasing the overall GH dose.

GH deficiency; infradian; IGFBP; ALS



* University of Manchester melissa.westwood{at}manchester.ac.uk







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.